{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:46:52Z","timestamp":1751435212254},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jpsychires.2016.01.016","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T17:47:59Z","timestamp":1454348879000},"page":"52-58","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Differential prevalence and demographic and clinical correlates of second-generation antipsychotic use in bipolar I versus bipolar II disorder"],"prefix":"10.1016","volume":"76","author":[{"given":"Dong Yeon","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn C.","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloni","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura D.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica N.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farnaz","family":"Hooshmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shefali","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence A.","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2016.01.016_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders 4th-text Revision Ed","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders 5th Ed","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.290.11.1517","article-title":"Suicide risk and treatments for patients with bipolar disorder","volume":"290","author":"Baldessarini","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v66n0116","article-title":"A\u00a0randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder","volume":"66","author":"Bowden","year":"2005","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hup.2326","article-title":"Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA","volume":"28","author":"Chen","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/YIC.0b013e32834e4c56","article-title":"Quetiapine for bipolar depression: a systematic review and meta-analysis","volume":"27","author":"Chiesa","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1461145709990344","article-title":"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis","volume":"13","author":"Cruz","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881111408461","article-title":"Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis","volume":"26","author":"De Fruyt","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib9","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders","author":"First","year":"1996"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1176\/ps.2006.57.5.666","article-title":"Racial differences in medication switching and concomitant prescriptions in the treatment of bipolar disorder","volume":"57","author":"Garver","year":"2006","journal-title":"Psychiatr. Serv."},{"issue":"Suppl.\u00a09","key":"10.1016\/j.jpsychires.2016.01.016_bib11","first-page":"49","article-title":"Antipsychotics in bipolar disorder","volume":"57","author":"Gelenberg","year":"1996","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.08m04301","article-title":"Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD","volume":"70","author":"Goldberg","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jad.2013.10.054","article-title":"Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000\u20132011","volume":"155","author":"Hooshmand","year":"2014","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib14","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1517\/14656566.2012.681377","article-title":"Quetiapine for the treatment of acute bipolar mania, mixed episodes and maintenance therapy","volume":"13","author":"Janicak","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/NDT.S41081","article-title":"Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study","volume":"9","author":"Jeong","year":"2013","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jad.2007.06.014","article-title":"Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders","volume":"108","author":"Judd","year":"2008","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/appi.ps.57.1.123","article-title":"Patterns of psychotropic medication use by race among veterans with bipolar disorder","volume":"57","author":"Kilbourne","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1176\/appi.ajp.159.4.567","article-title":"Racial disparities in antipsychotic prescription patterns for patients with schizophrenia","volume":"159","author":"Kuno","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1176\/ps.2008.59.5.540","article-title":"Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements","volume":"59","author":"Law","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib20","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1517\/14656566.2010.510835","article-title":"Atypical antipsychotic tolerability and switching strategies in bipolar disorder","volume":"11","author":"Liauw","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jpsychires.2016.01.016_bib21","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jad.2007.02.007","article-title":"Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms","volume":"100","author":"McIntyre","year":"2007","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Archiv General Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12888-014-0339-z","article-title":"Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior","volume":"14","author":"Miller","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib24","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.4088\/JCP.11m07424","article-title":"Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial","volume":"74","author":"Pathak","year":"2013","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1176\/appi.ps.201100092","article-title":"Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998\u20132009","volume":"63","author":"Pillarella","year":"2012","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hup.2445","article-title":"Pharmacotherapy in bipolar disorders during hospitalization and at discharge predicts clinical and psychosocial functioning at follow-up","volume":"29","author":"Pompili","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.31.8.806","article-title":"Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders","volume":"31","author":"Prabhakar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31802e5126","article-title":"Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002","volume":"27","author":"Reist","year":"2007","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1399-5618.2002.01195.x","article-title":"A\u00a0clinical monitoring form for mood disorders","volume":"4","author":"Sachs","year":"2002","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(03)00165-3","article-title":"Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)","volume":"53","author":"Sachs","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/11203840-000000000-00000","article-title":"Quetiapine: a review of its use in the management of bipolar depression","volume":"26","author":"Sanford","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","article-title":"Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Scherk","year":"2007","journal-title":"Archiv. Gen. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1399-5618.2007.00490.x","article-title":"Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials","volume":"9","author":"Smith","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jad.2014.07.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"168","author":"Suppes","year":"2014","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/15622970701317265","article-title":"Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies","volume":"9","author":"Suppes","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jad.2013.02.031","article-title":"First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo","volume":"150","author":"Suppes","year":"2013","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-0327(00)00162-2","article-title":"A\u00a0meta-analysis of the use of typical antipsychotic agents in bipolar disorder","volume":"65","author":"Tohen","year":"2001","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-2005-873162","article-title":"Quetiapine in the treatment of rapid-cycling bipolar II disorder with comorbid anxiety and social phobia \u2013 a case report","volume":"38","author":"Valerius","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/oxfordjournals.schbul.a033465","article-title":"Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders","volume":"26","author":"Wang","year":"2000","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2194-7511-1-10","article-title":"Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies","volume":"1","author":"Young","year":"2013","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.jpsychires.2016.01.016_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","article-title":"A\u00a0double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)","volume":"71","author":"Young","year":"2010","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.01.016_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/15622975.2012.665177","article-title":"A\u00a0randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder","volume":"15","author":"Young","year":"2014","journal-title":"World J. Biol. Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395616300152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395616300152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T21:42:07Z","timestamp":1617572527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395616300152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":44,"alternative-id":["S0022395616300152"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2016.01.016","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential prevalence and demographic and clinical correlates of second-generation antipsychotic use in bipolar I versus bipolar II disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2016.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}